InSightec and Gamida-Cell were two great hopes of Israel's biomed industry, but the one faces an uncertain future while Elbit Medical has relinquished the other in a debt settlement.
After six years as chair of the Israel Innovation Authority, Dr. Ami Appelbaum champions its independence from political control, and describes his fears and hopes for Israel's tech sector.